Protein (7)Kits (1)
Launched (8)
Human (8)
His Tag (1)Tag Free (6)- (1)
Unconjugated (7)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
ACA-H421b | HEK293 | Human Activin A / INHBA Protein, Tag Free | ![]() | |||
ACA-H424x | HEK293 | Human Latent Activin A / INHBA Protein, His Tag | ![]() | |||
ACA-H5116 | E. coli | Human Activin A / INHBA Superior Active Mutant Protein, premium grade | ||||
ACA-H5314 | CHO | Human Activin A / INHBA Protein, premium grade | ![]() | |||
ACA-H5315 | CHO | Human Activin A / INHBA Protein, Research Grade | ![]() | |||
CEA-C208 | - | rHuman Activin A ELISA Kit | ||||
GMP-ACAH37 | CHO | GMP Human Activin A / INHBA Protein | ![]() | |||
GMP-ACAH37GA02 | CHO | GMP Human Activin A / INHBA Protein | ![]() |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BLU-782 | BLU-782; IPN-60130 | Phase 2 Clinical | Blueprint Medicines Corp, Ipsen SA | Myositis Ossificans | Details |
| Zilurgisertib | INCB-000928; INCB-00928 | Phase 2 Clinical | Incyte Corp | Polycythemia Vera; Renal Insufficiency; Anemia; Myelodysplastic Syndromes; Ossification, Heterotopic; Multiple Myeloma; Primary Myelofibrosis; Myositis Ossificans; Thrombocythemia, Essential | Details |
| KER-047 | KER-047; TRND482477 | Phase 1 Clinical | National Center For Advancing Translational Sciences | Anemia, Iron-Deficiency; Myositis Ossificans | Details |
| Itacnosertib | TP-0184 | Phase 1 Clinical | Tolero Pharmaceuticals Inc, Sumitomo Dainippon | Solid tumours; Anemia | Details |
| BCX-9250 | BCX-9250 | Phase 1 Clinical | Biocryst Pharmaceuticals Inc | Myositis Ossificans | Details |
| HS135 | HS-135 | Phase 1 Clinical | 35Pharma Inc | Hypertension, Pulmonary; Heart Failure, Diastolic; Pulmonary Arterial Hypertension | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Momelotinib Dihydrochloride | CYT-387; GS-0387; GSK-3070785 | Approved | Gilead Sciences Inc, Cytopia Pty Ltd | Ojjaara, Omjjara | United States | Primary Myelofibrosis; Anemia | Glaxosmithkline Llc, Glaxosmithkline Plc | 2023-09-15 | Polycythemia Vera; Anemia; Myelodysplastic Syndromes; Neoplasms; Myeloproliferative Disorders; Pancreatic Intraductal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Splenomegaly; Thrombocythemia, Essential; Carcinoma, Non-Small-Cell Lung | Details |

[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email:order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
BettinastraBe 30, 60325 Frankfurt am Main










